# Campestanol

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/campestanol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 24-methylcholestanol, campestanol phytostanol, C28 saturated plant stanol, campesterol-derived stanol, 22,23-dihydrocampesterol

## Overview

Campestanol is a saturated plant stanol that reduces intestinal cholesterol absorption by competitively displacing dietary and biliary cholesterol from mixed micelles in the gut lumen, thereby lowering its uptake via NPC1L1 transporters. As a component of mixed phytostanol formulations at 2–3 g/day, it contributes to LDL-cholesterol reductions of approximately 8–14% in clinical trials, with some evidence suggesting additive benefits when combined with statin therapy.

## Health Benefits

- **LDL Cholesterol Reduction**: Campestanol disrupts micelle solubilization of cholesterol in the small intestine, reducing LDL-C by an estimated 8–14% at effective stanol doses of 2–3 g/day, according to meta-analyses of phytostanol-enriched food interventions.
- **Improved [Cardiovascular Risk](/ingredients/condition/heart-health) Profile**: By lowering LDL-C without significantly affecting HDL-C or triglycerides, campestanol contributes to an improved atherogenic lipid profile, potentially reducing long-term cardiovascular event risk in hypercholesterolemic individuals.
- **Additive Effect with Statins**: Clinical evidence indicates that phytostanols, including campestanol-containing mixtures, provide an additional 7–10% LDL-C reduction when added to statin therapy, operating through a complementary intestinal mechanism independent of HMG-CoA reductase inhibition.
- **Anti-Inflammatory Potential**: Preclinical cell studies suggest campestanol and related stanols may attenuate NF-κB signaling pathways, potentially reducing the expression of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as IL-6 and TNF-α, though this has not been confirmed in large human trials.
- **Prostate Health Support**: Phytosterols and phytostanols, including campestanol, have been investigated for modulating androgen-dependent pathways in prostate tissue; preliminary evidence suggests a role in supporting normal prostate cell function, though clinical data specific to campestanol remain limited.
- **Bile Acid Metabolism Modulation**: By reducing intestinal cholesterol absorption, campestanol indirectly increases hepatic conversion of cholesterol to bile acids, upregulating CYP7A1 activity and potentially supporting healthy bile acid pool turnover.
- **Blood Glucose and Metabolic Effects**: Emerging preclinical data suggest phytostanols may influence PPAR-gamma signaling and improve [insulin sensitivity](/ingredients/condition/weight-management) markers, though human evidence for campestanol specifically in metabolic syndrome contexts is sparse and requires further investigation.

## Mechanism of Action

Campestanol primarily acts by competitively displacing cholesterol from mixed micelles formed in the intestinal lumen during fat [digestion](/ingredients/condition/gut-health); because campestanol is poorly absorbed itself, this displacement reduces the amount of cholesterol available for uptake via the Niemann-Pick C1-like 1 (NPC1L1) transporter on enterocyte brush-border membranes. Once incorporated into intestinal cell membranes, campestanol may also reduce cholesterol esterification by acyl-CoA:cholesterol acyltransferase (ACAT), further limiting chylomicron-mediated cholesterol transport into the lymphatic system. Reduced hepatic cholesterol delivery secondarily upregulates LDL receptor expression on hepatocytes, accelerating clearance of circulating LDL particles from plasma. At the gene expression level, preclinical models indicate that phytostanols including campestanol may downregulate sterol regulatory element-binding protein (SREBP) targets and modulate ATP-binding cassette transporters ABCA1 and ABCG5/G8, influencing both cholesterol efflux and re-secretion into the intestinal lumen.

## Clinical Summary

The most robust clinical data supporting campestanol-containing interventions come from randomized trials of plant stanol ester-enriched margarines, where LDL-C reductions of 8–14% were consistently observed at 2–3 g/day total stanol doses in hypercholesterolemic populations, with effects maintained over 6–12 months. A notable 12-month RCT published by Miettinen and Gylling demonstrated that stanol ester consumption reduced LDL-C by 14.4% compared to placebo without significant changes to HDL-C or triglycerides, and without adverse effects on fat-soluble vitamin status at standard doses. Meta-analyses of stanol interventions confirm statistical significance and dose-response relationships, but effect sizes are modest (approximately 0.5–0.9 mmol/L absolute LDL-C reduction), and the [cardiovascular](/ingredients/condition/heart-health) hard-endpoint data (myocardial infarction, stroke reduction) remain extrapolated rather than directly demonstrated in adequately powered event-driven trials. Confidence in LDL-C surrogate endpoint data is high, but uncertainty remains regarding translation to reduced cardiovascular events, optimal long-term dosing, and campestanol's specific contribution within mixed stanol preparations.

## Nutritional Profile

Campestanol is a pure phytostanol compound (molecular formula C28H50O, molecular weight 400.70 g/mol) and does not contribute macronutrients, vitamins, or minerals in meaningful quantities when consumed at functional doses of 2–3 g/day. It is a waxy, lipophilic solid with very poor water solubility (<0.01 mg/mL), necessitating esterification with fatty acids (forming stanol esters) to achieve practical incorporation into food matrices and improve dispersibility. Bioavailability of campestanol is inherently low (<5% intestinal absorption), which is functionally advantageous as its cholesterol-lowering mechanism depends on gut-lumen competition rather than systemic absorption. At typical dietary exposure from unfortified foods, campestanol contributes an estimated 0.1–0.5 mg/day; therapeutic doses in fortified foods are 400–1,000-fold higher. Absorption may be mildly enhanced by concurrent fat intake, but high serum campestanol levels are considered a biomarker of elevated intestinal stanol absorption and may signal genetic susceptibility in sitosterolemia.

## Dosage & Preparation

- **Plant Stanol Ester Margarines/Spreads**: 2–3 g/day of total phytostanols (containing campestanol as a component), consumed with meals; the most clinically validated delivery format.
- **Soft-Gel Capsules**: Phytostanol ester capsules standardized to total stanol content; typical commercial doses range from 400–800 mg per capsule, targeting 2 g/day total stanols.
- **Fortified Foods (yogurts, milk, juices)**: 1–3 g/day total stanol content; effectiveness depends on co-consumption with fat-containing meals to support micelle formation and competitive displacement.
- **Standardization**: Commercial products are typically standardized to total phytostanol ester content (≥80% stanol esters by weight), with campestanol comprising approximately 20–35% of the stanol fraction depending on the vegetable oil source used in production.
- **Effective Dose Range**: 1.5–3 g/day of total plant stanols for meaningful LDL-C reduction; doses above 3 g/day show diminishing returns with no proportional additional benefit.
- **Timing**: Distributed across 2–3 meals per day is more effective than a single large dose; consumption with the largest fat-containing meal of the day optimizes cholesterol displacement efficiency.
- **Traditional Food Preparation**: No classical traditional preparation exists for isolated campestanol; dietary intake occurs passively through consumption of rapeseed oil, wheat bran, rye bread, and soybean-derived foods.

## Safety & Drug Interactions

Campestanol and mixed phytostanol formulations are generally well-tolerated at recommended doses of 2–3 g/day, with the most consistently reported concern being mild reduction in fat-soluble carotenoid (particularly beta-carotene and lycopene) and vitamin E plasma levels due to reduced micellar absorption; this effect is typically managed by adequate fruit and vegetable intake and does not reach clinically deficient levels in most healthy adults. Individuals with sitosterolemia (phytosterolemia), a rare autosomal recessive condition involving mutations in ABCG5 or ABCG8 transporters, absorb abnormally high quantities of plant stanols including campestanol, leading to elevated serum stanol levels and accelerated atherosclerosis; phytostanol supplements are therefore contraindicated in this population. There are no well-documented direct drug interactions at typical doses, though the additive LDL-lowering effect when combined with statins or ezetimibe warrants lipid monitoring to avoid excessive LDL reduction; patients on fat-soluble medications or those with fat malabsorption disorders should use caution. Pregnancy and lactation safety has not been established in adequate human studies, and regulatory bodies including EFSA advise that pregnant women, breastfeeding mothers, and young children do not require phytostanol supplementation and should avoid high-dose fortified products.

## Scientific Research

The majority of clinical evidence for campestanol derives from studies using mixed phytostanol formulations, most notably the Benecol product line containing plant stanol esters where campestanol-derived stanol ester constitutes a portion of the active ingredient alongside sitostanol; isolating campestanol's independent contribution is therefore methodologically difficult. A landmark series of Finnish randomized controlled trials by Miettinen et al. in the 1990s established that plant stanol ester margarines reduced LDL-C by 10–14% in hypercholesterolemic adults, forming the evidentiary basis for regulatory approvals, though campestanol was studied as part of a mixture. A 2014 Cochrane-style systematic review of phytosterol and phytostanol interventions encompassing over 40 RCTs confirmed consistent LDL-C reductions of 8–12% at 2–3 g/day doses, but could not disaggregate campestanol-specific effects from sitostanol or other stanol components. Evidence for campestanol's purported prostate health benefits remains largely preclinical, derived from androgen receptor binding assays and animal models, with no adequately powered human RCTs specifically examining campestanol in isolation for prostate outcomes.

## Historical & Cultural Context

Campestanol as an isolated compound has no traditional medicinal history; it was not identified as a distinct phytostanol until the mid-20th century when analytical chemistry techniques enabled separation of individual sterols and stanols from plant oils. Its precursor, campesterol, has been present in human diets throughout agricultural history via grain and oilseed consumption, and the broader category of plant sterols was recognized in folk botanical traditions—seeds and cold-pressed oils rich in phytosterols were historically used in Ayurvedic medicine as cardiovascular tonics under the concept of Snigdha (unctuous) and heart-nourishing foods. The commercial significance of campestanol emerged in the 1990s following Finnish research demonstrating that plant stanol esters in functional foods could meaningfully lower cholesterol, leading to the introduction of Benecol margarine in Finland in 1995—the first commercially marketed phytostanol-enriched food product. Regulatory recognition followed, with the European Food Safety Authority and the U.S. FDA authorizing qualified health claims for phytosterols and phytostanols in reducing LDL cholesterol, establishing campestanol-containing mixtures as among the earliest phytochemicals to receive formal regulatory endorsement for [cardiovascular risk](/ingredients/condition/heart-health) reduction.

## Synergistic Combinations

Campestanol-containing phytostanol mixtures demonstrate well-documented additive LDL-lowering synergy with HMG-CoA reductase inhibitors (statins), as statins reduce endogenous cholesterol synthesis while campestanol reduces intestinal cholesterol absorption, producing a complementary dual-pathway effect that yields an additional 7–10% LDL-C reduction beyond statin monotherapy. Combining phytostanols with soluble fiber sources such as [beta-glucan](/ingredients/condition/immune-support) (from oats) or psyllium husk may provide further synergy, as soluble fiber reduces bile acid reabsorption and increases hepatic cholesterol catabolism, complementing campestanol's micellar displacement mechanism. Omega-3 fatty acids (EPA/DHA) pair well with campestanol-enriched foods by addressing triglyceride and HDL-C parameters not significantly affected by stanols alone, creating a more comprehensive [cardiovascular](/ingredients/condition/heart-health) lipid-modifying stack.

## Frequently Asked Questions

### What is campestanol and how does it differ from campesterol?

Campestanol is the saturated form (phytostanol) of campesterol, differing by the absence of a double bond at the C5 position of the sterol ring; this structural difference makes campestanol more resistant to oxidation and less readily absorbed from the intestine. Campesterol is a phytosterol found naturally in plant foods, while campestanol is typically produced commercially via hydrogenation of campesterol and used in functional foods specifically for its cholesterol-lowering properties.

### How much campestanol do I need to lower my cholesterol?

Clinical trials using plant stanol ester formulations containing campestanol as a component demonstrate that 2–3 g/day of total phytostanols is the effective therapeutic range, producing LDL-C reductions of approximately 8–14%. This is typically achieved through 2–3 daily servings of fortified foods such as stanol-enriched margarine or yogurt, consumed with fat-containing meals to optimize the cholesterol displacement mechanism in the intestine.

### Is campestanol safe to take long-term?

Long-term studies of up to 12 months with plant stanol ester products containing campestanol show an acceptable safety profile in healthy adults, with the primary concern being modest reductions in plasma carotenoid and vitamin E levels that can be offset by increased fruit and vegetable consumption. However, individuals with sitosterolemia must avoid campestanol entirely, and safety data beyond 12 months in diverse populations remain limited, so consultation with a healthcare provider is advisable for extended use.

### Can campestanol be taken with statins?

Yes, combining campestanol-containing phytostanol formulations with statins is supported by clinical evidence showing additive LDL-C reductions of approximately 7–10% beyond statin therapy alone, since they operate through complementary mechanisms—statins inhibit hepatic cholesterol synthesis while campestanol reduces intestinal cholesterol absorption. This combination is used in clinical practice, but lipid levels and fat-soluble nutrient status should be monitored periodically, and the decision should be made with a physician's guidance.

### What foods naturally contain campestanol?

Campestanol occurs naturally in plant foods at very low concentrations, primarily in rapeseed (canola) oil, soybean oil, wheat bran, rye, and corn, where it is present at microgram-to-low-milligram levels per serving—far below the 2–3 g/day therapeutic threshold. To achieve clinically meaningful intake, fortified functional foods such as plant stanol ester margarines, enriched dairy products, or encapsulated phytostanol supplements are necessary, as natural dietary exposure provides only approximately 0.1–0.5 mg/day.

### What is the clinical evidence for campestanol's cholesterol-lowering effectiveness?

Meta-analyses of phytostanol-enriched food interventions demonstrate that campestanol reduces LDL cholesterol by 8–14% at effective doses of 2–3 g/day, making it one of the most well-documented natural compounds for cholesterol management. This evidence comes primarily from randomized controlled trials using campestanol-fortified functional foods rather than isolated supplements, which represent the strongest evidence base for its cardiovascular benefits.

### Who is most likely to benefit from campestanol supplementation?

Individuals with elevated LDL cholesterol levels, particularly those seeking non-pharmaceutical approaches or those intolerant to statins, are most likely to benefit from campestanol. People with metabolic syndrome or mild-to-moderate hypercholesterolemia may see meaningful improvements, though those with genetic familial hypercholesterolemia typically require stronger interventions.

### How does campestanol absorption work, and what factors affect how well it works?

Campestanol works by competing with dietary cholesterol for incorporation into micelles in the small intestine, thereby reducing cholesterol absorption rather than being absorbed itself in significant amounts. Fat-soluble vitamin absorption (vitamins A, D, E, K) may be slightly reduced at high doses, and consuming campestanol with meals containing dietary fat optimizes its cholesterol-blocking mechanism.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*